Is Metformin Good for You? Benefits and Side Effects

Metformin is one of the most thoroughly studied medications in modern medicine, and for most people with type 2 diabetes, the answer is yes: it lowers blood sugar effectively, carries a low risk of dangerous blood-sugar crashes, and does not cause weight gain. But the question has grown well beyond diabetes. Researchers have linked metformin to reduced cancer risk, lower dementia rates, and even slower aging in animal models, turning a decades-old drug into a surprisingly active area of investigation. The picture is not uniformly positive, though, with real side effects that affect a meaningful share of users and emerging concerns about interactions with exercise.

How Metformin Actually Works

The textbook explanation used to be simple: metformin tells the liver to stop pumping out so much glucose. That is true, but it turns out to be only part of the story. The drug acts through several overlapping pathways, including effects on the gut and on cellular energy sensors. One key target is an enzyme called AMPK, which acts as a kind of fuel gauge inside cells. When metformin activates AMPK, cells behave as though energy is scarce, which among other things dials down glucose production.

1PubMed Central. The mechanisms of action of metformin

Researchers have also found that metformin inhibits a step in mitochondrial energy production known as complex I. This triggers a cascade of metabolic changes that go beyond blood sugar, touching inflammation, fat metabolism, and even how cells age and recycle damaged components. The fact that metformin works through so many channels helps explain why its effects seem to reach into areas far removed from diabetes.

2Endocrine Reviews. Cellular and Molecular Mechanisms of Metformin Action

The Core Job: Blood Sugar Control in Type 2 Diabetes

Metformin has been the go-to first-line treatment for type 2 diabetes for decades, and the evidence supporting that position remains strong. In both lean and overweight patients, it lowers HbA1c, the standard measure of average blood sugar over the previous two to three months, by roughly one percentage point in the first year of use.

3PubMed Central. Long-term effect of metformin on blood glucose control in non-obese patients with type 2 diabetes mellitus

What makes metformin especially appealing compared to many other diabetes drugs is what it does not do. It does not cause significant weight gain, carries very little risk of hypoglycemia (the dangerous blood-sugar drops that complicate insulin and certain other medications), and has neutral-to-positive effects on cholesterol and blood pressure.

4PubMed. Metformin–the gold standard in type 2 diabetes: what does the evidence tell us?

There is a common misconception that metformin only works well in overweight or obese patients. Research comparing non-obese and obese groups found that blood sugar improvements were similar in both, though leaner patients needed a lower dose to achieve the same effect.

3PubMed Central. Long-term effect of metformin on blood glucose control in non-obese patients with type 2 diabetes mellitus

Preventing Diabetes in People With Prediabetes

The U.S. Diabetes Prevention Program, one of the most influential diabetes studies ever conducted, showed that metformin reduced the progression from prediabetes to full-blown type 2 diabetes by about 31% over three years, compared with a placebo. Lifestyle changes, including moderate exercise and weight loss, performed even better, cutting risk by 58%. But the remarkable finding is how durable both approaches turned out to be. Over roughly 21 years of follow-up, metformin continued to delay diabetes onset, extending the average time people stayed diabetes-free by about two and a half years compared with placebo.

5The Lancet Diabetes & Endocrinology. Long-term effects of lifestyle intervention or metformin on diabetes incidence and bodyweight in the Diabetes Prevention Program Outcomes Study

Adding metformin on top of lifestyle changes also appears to offer incremental benefit. A meta-analysis of randomized trials found that the combination further reduced HbA1c and lowered the incidence of type 2 diabetes by about 15% beyond what lifestyle changes alone achieved.

6PubMed Central. Metformin plus lifestyle interventions versus lifestyle interventions alone for the delay or prevention of type 2 diabetes in individuals with prediabetes

One important caveat: despite successfully delaying diabetes, long-term metformin use in the prediabetes population did not translate into fewer heart attacks or strokes over 21 years of follow-up. Preventing diabetes is clearly valuable for quality of life and avoiding complications, but the cardiovascular payoff, at least in people who start out without diabetes, has not materialized in the trial data.

7PubMed Central. Effects of Long-term Metformin and Lifestyle Interventions on Cardiovascular Events in the Diabetes Prevention Program and Its Outcome Study

Weight Loss and Appetite

Metformin is not a weight-loss drug in the way that newer GLP-1 receptor agonists are, but many people on it do lose a modest amount of weight or at least avoid gaining it. Research has identified a specific hormone, GDF15, that appears to mediate this effect. When you take metformin, your body ramps up production of GDF15, which acts on receptors in the brainstem to suppress appetite and reduce food intake.

8PubMed. Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss

Studies in mice confirmed this connection directly: animals genetically engineered to lack GDF15 or its receptor gained weight on a high-fat diet regardless of whether they received metformin, while normal mice given metformin were protected from that weight gain.

9Nature. GDF15 mediates the effects of metformin on body weight and energy balance

In clinical practice, the weight effect is typically modest, often a few pounds at most. People hoping for dramatic results will be disappointed. But for a diabetes medication, staying weight-neutral or losing a small amount is a meaningful advantage, especially since several older drug classes tend to cause weight gain.

PCOS and Fertility

Polycystic ovary syndrome is one of the best-established off-label uses for metformin. In women with PCOS, the drug reduces androgen levels, improves insulin sensitivity, and can help restore regular menstrual cycles and ovulation.

10PubMed Central. Role of Metformin in Polycystic Ovary Syndrome (PCOS)-Related Infertility

That said, guidelines are clear that metformin should not be the first thing prescribed when the primary goal is getting pregnant. Standard ovulation-induction medications produce substantially higher ovulation, pregnancy, and live-birth rates. Where metformin does shine is as a supporting player: in women who do not respond to first-line ovulation drugs alone, adding metformin improved ovulation rates and pregnancy rates.

11PubMed. Role of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline 12PubMed. Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome

Cancer Risk Reduction

Some of the most intriguing data around metformin involve cancer. A large systematic review and meta-analysis published in the Journal of the National Cancer Institute found that metformin use was associated with roughly a 21% lower risk of gastrointestinal cancers, with smaller but statistically significant reductions in urologic and blood cancers as well.

13PubMed Central. Association of metformin use and cancer incidence: a systematic review and meta-analysis

Earlier meta-analyses pointed to particularly strong associations with pancreatic cancer and liver cancer, while the connection to breast and prostate cancer was weaker and not statistically significant.

14PubMed. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis

The caveats here are worth spelling out. Nearly all of the cancer data come from observational studies comparing people with diabetes who happen to take metformin against people with diabetes on other treatments. That study design cannot fully separate the drug’s effect from other differences between the groups. It is plausible that metformin’s anti-cancer signal partly reflects the fact that people prescribed metformin tend to be healthier, earlier in their disease course, or less likely to have conditions that independently raise cancer risk. The biological plausibility is there: metformin activates pathways that suppress cell growth and promote cellular housekeeping. But no large randomized trial has proven metformin prevents cancer in humans, so the strength of the evidence is real but not definitive.

Brain Health and Dementia

Multiple large observational studies have linked metformin use to a lower risk of dementia in people with type 2 diabetes. In one large Taiwanese cohort study, long-term metformin users had roughly half the dementia incidence of non-users, and the benefit appeared to grow with longer use. People who had been on metformin for more than about five years showed the lowest risk.

15PubMed Central. Metformin and the Risk of Dementia in Type 2 Diabetes Patients

A separate U.S. study approached the question from an unusual angle: instead of comparing users to non-users, it compared people who stopped metformin early to those who continued routine use. Those who stopped sooner had about a 21% higher risk of developing dementia, which translates to roughly a 17% protective effect of staying on the medication.

16JAMA Network Open. Metformin Cessation and Dementia Incidence

Again, these are observational findings. A randomized trial would be needed to say with confidence that metformin prevents dementia rather than simply being taken by people who are at lower risk for other reasons. But the consistency across populations and study designs has been enough to spur serious interest, and clinical trials specifically testing metformin for brain aging are underway.

Common Gastrointestinal Side Effects

If metformin has an Achilles’ heel, it is what it does to the gut. Nausea, diarrhea, bloating, and abdominal discomfort are the most frequent complaints, and they are the leading reason people discontinue the drug. These symptoms typically appear soon after starting metformin or after a dose increase, and they often improve within a few weeks as the body adjusts.

What many people and some clinicians do not realize is that gastrointestinal problems can also emerge years into stable treatment. Delayed-onset chronic diarrhea is an underrecognized phenomenon that can cause significant weight loss and is sometimes misattributed to other gastrointestinal conditions before anyone thinks to blame the metformin.

17PubMed Central. A Common Drug Causing a Common Side Effect at an Uncommon Time: Metformin-Induced Chronic Diarrhea and Weight Loss After Years of Treatment

If you have been on metformin for years and develop unexplained diarrhea, it is worth raising the possibility with your doctor rather than assuming the drug has been ruled out by the timeline alone.

Vitamin B12 Deficiency

Long-term metformin use interferes with the absorption of vitamin B12, and this is not a trivial concern. A study using the NIH’s All of Us research database found that people on metformin for extended periods had a 67% higher likelihood of B12 deficiency compared to non-users.

18PubMed. Associations between long-term metformin use, the risk of vitamin B12 deficiency, and neuropathy

This matters because B12 deficiency can cause nerve damage that looks and feels exactly like diabetic neuropathy: tingling, numbness, and pain in the hands and feet. When both diabetes and metformin are in the picture, there is a real risk that the neuropathy gets chalked up entirely to the diabetes while a correctable nutritional deficiency goes untreated. Research has found that B12-related neuropathy improves with supplementation when the deficiency is caught.

19PubMed Central. Metformin-induced vitamin B12 deficiency: An underdiagnosed cause of diabetic neuropathy

Some clinical guidelines now recommend periodic B12 monitoring in people who have been on metformin for several years. If you are a long-term user, asking for a B12 level check is reasonable, especially if you have any symptoms of neuropathy.

Lactic Acidosis and Kidney Function

Lactic acidosis, a dangerous buildup of lactic acid in the blood, has long been the bogeyman of metformin prescribing. Historically, doctors were cautious about using the drug in anyone with even mildly reduced kidney function because a related older drug, phenformin, was pulled from the market over this risk. But the evidence for metformin itself paints a much more reassuring picture.

A large community-based study found that metformin use was not associated with any increased risk of acidosis overall, and that the risk remained statistically indistinguishable from other diabetes treatments even in people with moderately reduced kidney function. The danger zone appears only at severely reduced kidney filtration rates, below about 30 mL/min, where metformin use was associated with roughly double the risk of acidosis.

20JAMA Internal Medicine. Association of Metformin Use With Risk of Lactic Acidosis Across the Range of Kidney Function

This evidence has led to a significant shift in prescribing guidelines. Many health systems now allow metformin to be used at reduced doses in people with moderate kidney impairment, reserving the full stop only for severe kidney disease. If you have been told you cannot take metformin because of your kidneys, it may be worth revisiting that conversation with your doctor, particularly if your kidney function is only mildly reduced.

Metformin Can Blunt Exercise Benefits

This is perhaps the most surprising finding in recent metformin research, and the one most relevant to people considering the drug for its potential anti-aging effects. A study in older adults found that taking metformin while doing aerobic exercise training blunted the expected improvements in both cardiorespiratory fitness (VO2 max) and insulin sensitivity. Metformin also blocked the increase in skeletal muscle mitochondrial function that normally comes with regular exercise.

21PubMed Central. Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults

A systematic review and meta-analysis confirmed the pattern: people who combined metformin with exercise training showed a consistently smaller improvement in peak aerobic capacity, on the order of one mL/kg/min less than exercise alone. That may sound small, but improvements in VO2 max at that scale are associated with meaningful differences in mortality risk and blood sugar control.

22eClinicalMedicine. The effects of metformin and exercise training on cardiorespiratory, blood pressure, and metabolic adaptations across the spectrum of glucose dysregulation

The tension here is uncomfortable. Metformin and exercise both improve health through overlapping pathways, particularly involving mitochondria and AMPK. When both are active at once, metformin’s inhibition of mitochondrial function appears to partially counteract the very adaptations exercise is trying to build. For people with diabetes who need metformin for blood sugar control, this trade-off is likely worth it. But for healthy people eyeing metformin as a longevity drug, the possibility that it could undermine their exercise program is a genuine concern that deserves attention.

Extended-Release vs. Immediate-Release

Metformin comes in two main formulations: immediate-release (IR), which is typically taken two or three times daily, and extended-release (XR), which is usually taken once a day. The blood-sugar-lowering effect is comparable between the two, but they differ meaningfully in how people tolerate them.

A prospective cohort study found that after six months, about 45% of people on the immediate-release version reported gastrointestinal side effects, compared with roughly 25% on the extended-release form. Rates of diarrhea specifically were higher in the immediate-release group, and fewer people on extended-release had to interrupt their treatment because of gut problems.

23PubMed Central. Comparative effectiveness of immediate-release and extended-release metformin on gastrointestinal tolerability, quality of life, and treatment satisfaction

Adherence also tends to be better with the extended-release version, likely because taking a pill once a day is simpler than remembering it two or three times.

24PubMed Central. Long-Acting Metformin Vs. Metformin Immediate Release in Patients With Type 2 Diabetes: A Systematic Review

If gastrointestinal side effects are making metformin hard to tolerate, switching from immediate-release to extended-release is often the first thing to try before giving up on the drug entirely. Taking it with food and starting at a low dose that is increased gradually also helps.

Metformin During Pregnancy

Metformin is increasingly used during pregnancy, particularly for gestational diabetes and in women with PCOS who conceive while already on the drug. Unlike insulin, metformin crosses the placenta, meaning the fetus is exposed to concentrations similar to the mother’s. A register-based cohort study found no increased risk of major long-term adverse outcomes in children exposed to metformin in utero compared to those whose mothers used insulin.

25PubMed Central. Metformin in pregnancy and risk of adverse long-term outcomes: a register-based cohort study

However, the picture grows more nuanced with longer follow-up. Meta-analyses report that babies exposed to metformin tend to have slightly lower birth weight but then show accelerated growth after birth. The longest placebo-controlled follow-up, tracking children to ages five through ten, found a higher prevalence of central obesity in the metformin-exposed group.

26PubMed Central. Metformin use in pregnancy: What about long-term effects in offspring?

Whether that childhood weight gain persists into adulthood or carries lasting metabolic consequences remains unclear. Follow-up data on cardiometabolic and brain development outcomes are still limited and inconsistent.

27PubMed Central. Long-term effects of metformin on offspring health: A review of current evidence and future directions

The Anti-Aging Question

Metformin slows aging in worms, flies, and mice, and observational studies in humans suggest that people with diabetes who take metformin sometimes outlive non-diabetic people who do not take it. These findings, along with metformin’s ability to target multiple aging-related cellular processes, have generated enormous enthusiasm in the longevity community.

28PubMed. Metformin as a geroprotector: experimental and clinical evidence

The drug influences a striking range of aging hallmarks, including nutrient sensing, mitochondrial function, inflammation, cellular recycling, and even telomere maintenance.

29PubMed Central. Metformin in aging and aging-related diseases: clinical applications and relevant mechanisms

But the honest assessment is that we do not yet know whether metformin extends healthy lifespan in people who do not have diabetes. The mechanisms are suggestive, not proven for that purpose. Not everyone who takes metformin responds the same way, and as discussed above, the drug may interfere with exercise adaptations that are themselves among the most powerful anti-aging interventions we have. Before metformin becomes a mainstream anti-aging therapy, researchers need a much more detailed understanding of who benefits and who does not.

30PubMed Central. Metformin as Anti-Aging Therapy: Is It for Everyone?

Where Metformin Fits Among Newer Diabetes Drugs

The diabetes drug landscape has changed dramatically in recent years with the arrival of SGLT2 inhibitors and GLP-1 receptor agonists, the drug class that includes semaglutide. These newer medications have something metformin has never convincingly demonstrated in randomized trials: proven reductions in cardiovascular events like heart attacks, strokes, and heart failure hospitalizations in people with established heart disease.

31PubMed Central. Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists: JACC Focus Seminar

That does not mean metformin is obsolete. It remains inexpensive, available as a generic, well-understood after decades of use, and effective at controlling blood sugar without causing weight gain or dangerous blood sugar lows. For many patients, particularly those without established cardiovascular disease, it continues to be a sensible starting point. But for people at high cardiovascular risk, guidelines increasingly favor adding or even prioritizing the newer drug classes that have demonstrated clear heart and kidney benefits in randomized trials. The practical reality for many patients is that metformin ends up as part of a combination rather than a solo act, which is a reasonable reflection of its strengths and limitations.